Literature DB >> 1676753

Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa.

L Guillevin1, B Jarrousse, C Lok, F Lhote, J P Jais, D Le Thi Huong Du, A Bussel.   

Abstract

We attempted to define the most effective treatment for polyarteritis nodosa and Churg-Strauss angiitis, with a prospective, randomized, multicenter trial of cyclophosphamide in conjunction with corticosteroids and plasma exchanges, compared to corticosteroids and plasma exchanges. A total of 71 patients who fulfilled clinical, histological and/or arteriographic diagnostic criteria were randomly designated to receive either prednisone and plasma exchanges (group A, n = 39) or cyclophosphamide, prednisone and plasma exchanges (group B, n = 32). The end points of the study were control of the disease (recovery and remission) and death. Upon study entry clinical and laboratory features did not differ in the 2 groups. Treatment was stopped in 19 patients because of ineffectiveness in 10 (9 in Group A) and side effects in 9 (8 in Group B). Initial control of the disease was similar in both groups. At 5 years, 27 patients had completely recovered and 14 patients were in clinical remission. The cyclophosphamide-prednisone-plasma exchange association was beneficial in preventing relapses during longterm followup. Nineteen deaths were reported during the followup period. There was no difference between the 10 year cumulative survival rates of the 2 groups (respectively, 72 and 75%). Thus, the association of cyclophosphamide with corticosteroids and plasma exchanges reduced the incidence of relapses and improved the quality of the clinical response to therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676753

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  27 in total

1.  Churg-Strauss syndrome.

Authors:  P Ramnarayan; S Sowmya; N Biswal; P Nalini; C Ratnakar
Journal:  Indian J Pediatr       Date:  1998 May-Jun       Impact factor: 1.967

Review 2.  Management of virus-induced systemic vasculitides.

Authors:  Loïc Guillevin; Pascal Cohen
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 3.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

Review 4.  Churg-Strauss syndrome.

Authors:  M Conron; H L Beynon
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

5.  [Polyarteritis nodosa: differential diagnostics and therapy].

Authors:  J H Schirmer; K Holl-Ulrich; F Moosig
Journal:  Z Rheumatol       Date:  2014-12       Impact factor: 1.372

6.  Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.

Authors:  M G Danieli; M Cappelli; G Malcangi; F Logullo; A Salvi; G Danieli
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

7.  Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.

Authors:  Ravi Suppiah; Oliver Flossman; Chetan Mukhtyar; Federico Alberici; Bo Baslund; Denise Brown; Nadeem Hasan; Julia Holle; Zdenka Hruskova; David Jayne; Andrew Judge; Mark A Little; Peter A Merkel; Alessandra Palmisano; Philip Seo; Coen Stegeman; Vladimir Tesar; Augusto Vaglio; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2010-08-24       Impact factor: 19.103

8.  28-year-old woman with rapidly progressive shortness of breath. Diagnosis: CSS.

Authors:  Douglas L Nguyen; Eva M Carmona; Randall S Edson
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

Review 9.  Eosinophilic pneumonias.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

10.  A case of Churg-Strauss vasculitis complicated by small bowel necrosis.

Authors:  G N Schoretsanitis; D M Wakely; T Maddox; C Wastell
Journal:  Postgrad Med J       Date:  1993-10       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.